Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Merus Announced Based On The Company’s Current Operating Plan, Existing Cash, Cash Equivalents And Marketable Securities, Expected To Fund Merus’ Operations Into Second Half 2025

Merus N.V. (Nasdaq: MRUS) today provided its 2023 outlook. - As of year-end 2022, more than 150 patients with NRG1 gene fusion positive ("NRG1+") cancer have been treated with zenocutuzumab ("Zeno") monotherapy - Petosemtamab clinical update planned for first half of 2023

MRUS